FDA Grants Approval for Fluvoxamine Maleate ANDA220447 by Zydus Pharms
The FDA has granted approval for ANDA220447, a generic version of Fluvoxamine Maleate, submitted by Zydus Pharms.
Published: July 25, 2026
Updated: July 25, 2026
Author: Humanexa Intelligence
Therapeutic area: Psychiatry / SSRI
Asset: FDA
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Asset
FDA
Indication
Signal assessment
Signal strength
high
Confidence level
moderate
Signalhigh
Confidencemoderate
Why it matters
The FDA's approval of Zydus Pharms' generic Fluvoxamine Maleate introduces significant competition in the SSRI market. This could impact pricing and market share for existing branded products, necessitating strategic adjustments from current market players.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor market entry timing and pricing strategies of Zydus Pharms and competitors.
Related companies & assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.